Ramucirumab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer
Trial Timeline
Dec 1, 2013 → Feb 1, 2016
NCT ID
NCT01983878About Ramucirumab
Ramucirumab is a phase 2 stage product being developed by Eli Lilly for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01983878. Target conditions include Gastric Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02065765 | Pre-clinical | Completed |
| NCT04557384 | Phase 1 | Terminated |
| NCT03745430 | Phase 1/2 | Completed |
| NCT02564198 | Phase 1 | Completed |
| NCT02443883 | Phase 2 | Completed |
| NCT01983878 | Phase 2 | Completed |
| NCT01682135 | Phase 1 | Completed |
| NCT00721162 | Phase 2 | Completed |
| NCT00515697 | Phase 2 | Completed |
Competing Products
20 competing products in Gastric Cancer